News

News

RareCyte® reports significant 2021 growth of Precision Biology Services business and customer uptake of Orion Spatial Biology instruments and reagents

Seattle, WA, January 6th, 2022 - RareCyte Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021. They also saw significant uptake by early adopters of their Orion instruments and consumables by global key opinion leaders in support of fast, subcellular whole slide spatial analysis.

Read more...

RareCyte® Secures $24M Financing to Advance the Orion Spatial Biology Platform and Expand Global Commercial Channels

Seattle, WA, September 9, 2021 – RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform and further global expansion for the Company’s portfolio of instruments and consumables.

Read more...

RareCyte announces new rare cell detection kit for non-epithelial cancers

Seattle, WA, September 7, 2021 – RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers, such as sarcomas and melanoma, as well as other non-tumor rare cell populations. Together with the AccuCyte® Sample Preparation System, the Cell Discovery Kit provides sensitive and specific rare cell identification.

Read more...

RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies

Seattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

Seattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

RareCyte® announces the Orion spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis

Seattle, WA. July 16, 2020 – RareCyte, Inc., a company focused on providing Precision Biology solutions for life sciences, announced today the Orion spatial biology analysis platform applicable to translational and clinical research. Orion is based on a patented and proprietary technology that will accelerate immuno-oncology and infectious disease research. Orion enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment in a matter of hours, in contrast to existing technologies that require several days to weeks.

Read more...

Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology Applications

Berlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.

Read more...

RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay

Seattle, WA, February 27, 2020 - RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research.

Read more...

RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing

SEATTLE, Dec. 19, 2019 - RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its instrument and consumables platform used in research and clinical markets. The $22M investment was led by HealthQuest Capital, with participation from 5AM Ventures and company founder, Ron Seubert.

Read more...

RareCyte expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit

SEATTLE, Oct. 31, 2019 /PRNewswire/ -- RareCyte announces an addition to the RarePlex® Staining Kit product line, enabling customers to evaluate HER2 and ER expression on circulating tumor cells (CTCs) in their own laboratory. HER2 and ER are biomarkers that direct treatment recommendations for invasive breast cancer, and liquid biopsy offers a blood-based method to evaluate biomarker expression for insight into receptor status, response to treatment, and potentially therapy selection in clinical research.

Read more...